Overview
UNCY market data
Price History
UNCY price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$5.48 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.71 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.71 – $8.74 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $141.5 · P/B 4.11 · P/S 31.15.
Company News
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading WarningsBenzinga · Jul 16, 2026, 5:29 PM
UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud InvestigationGlobenewswire Inc · Jul 13, 2026, 7:15 PM
ALHC ALERT: Block & Leviton Investigating Alignment Healthcare, Inc. For Possible Securities Fraud; Investors Should Contact Block & Leviton to Learn MoreGlobenewswire Inc · Jul 8, 2026, 10:15 PM
8-K filing — Unicycive Therapeutics, Inc. (UNCY)SEC EDGAR · Jul 2, 2026, 2:30 PM
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13Benzinga · Jul 1, 2026, 3:40 PM
Noble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50Benzinga · Jul 1, 2026, 2:00 PM
HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $15Benzinga · Jun 30, 2026, 5:35 PM
B. Riley Securities Maintains Buy on Unicycive Therapeutics, Maintains $22 Price TargetBenzinga · Jun 30, 2026, 5:05 PM
Nasdaq Gains Over 300 Points; Chicago PMI Falls In JuneBenzinga · Jun 30, 2026, 4:10 PM
Why Is Unicycive Therapeutics Stock Falling Tuesday?Benzinga · Jun 30, 2026, 3:10 PM